Stay updated on SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.

Latest updates to the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page
- Check5 days agoChange DetectedThe footer’s site revision changes from v3.7.0 to v3.7.1; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA 403 Forbidden error page is now displayed when accessing the study record NCT03238027, replacing the usual content. This indicates an access restriction or server-side issue preventing viewing the study details.SummaryDifference23%

- Check47 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6 in the page footer. This indicates a minor version update with no evident changes to the study details presented on the page.SummaryDifference0.0%

- Check68 days agoChange DetectedThe page revision tag was updated to v3.6.5 from v3.6.4, indicating a minor update to the page. There are no visible changes to the study details or content.SummaryDifference0.0%

- Check82 days agoChange DetectedAdded a Publications section with a PubMed citation for a 2025 paper and a note that PubMed data auto-populates. Updated the revision entry to v3.6.4, replacing v3.6.3.SummaryDifference0.3%

- Check104 days agoChange DetectedThe revision number on the page was updated from v3.6.2 to v3.6.3, representing a software update to the page's rendering or maintenance without altering the study content.SummaryDifference0.0%

Stay in the know with updates to SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SNDX-6352 & Durvalumab in Solid Tumors Clinical Trial page.